Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: an analysis using continuous glucose monitoring.

Bergenstal RM, Strock E, Mazze R, Powers MA, Monk AM, Richter S, Souhami E, Ahren B.

Diabetes Metab Res Rev. 2016 Dec 29. doi: 10.1002/dmrr.2879. [Epub ahead of print]

PMID:
28032465
2.

Addition of once daily prandial lixisenatide to basal insulin therapy in patients with type-2 diabetes results in a reduction of HbA1c as an effect of postprandial glucose lowering.

Fleischmann H, Göke R, Bramlage P.

Diabetes Metab Syndr. 2016 Dec 12. pii: S1871-4021(16)30238-7. doi: 10.1016/j.dsx.2016.12.014. [Epub ahead of print]

PMID:
27986406
3.

What next after basal insulin? Treatment intensification with lixisenatide in Asian patients with type 2 diabetes mellitus.

Chan WB, Luk A, Chow WS, Yeung VT.

J Diabetes. 2016 Dec 15. doi: 10.1111/1753-0407.12515. [Epub ahead of print] Review.

PMID:
27976513
4.

Lixisenatide -- Benefit Assessment According to §35a Social Code Book V [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2013 Jun 13.

5.

Insulin degludec, Lixisenatide, and Patiromer sorbitex calcium.

Hussar DA, White MN.

J Am Pharm Assoc (2003). 2016 Nov - Dec;56(6):691-694. doi: 10.1016/j.japh.2016.10.002. No abstract available.

PMID:
27836130
6.

Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.

Hanefeld M, Raccah D, Monnier L.

Expert Opin Drug Metab Toxicol. 2016 Nov 3:1-11. [Epub ahead of print]

PMID:
27776453
8.

Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats.

Cai HY, Wang ZJ, Hölscher C, Yuan L, Zhang J, Sun P, Li J, Yang W, Wu MN, Qi JS.

Behav Brain Res. 2017 Feb 1;318:28-35. doi: 10.1016/j.bbr.2016.10.033.

PMID:
27776993
9.

Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials.

Blonde L, Chava P, Dex T, Lin J, Nikonova EV, Goldenberg RM.

Diabetes Obes Metab. 2016 Oct 21. doi: 10.1111/dom.12815. [Epub ahead of print]

PMID:
27767249
10.

Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A meta-analysis from the GetGoal programme.

Broglio F, Mannucci E, Napoli R, Nicolucci A, Purrello F, Nikonova E, Stager W, Trevisan R.

Diabetes Obes Metab. 2016 Oct 20. doi: 10.1111/dom.12810. [Epub ahead of print]

PMID:
27762096
11.

[Lixisenatide in patients with type 2 diabetes and obesity: Beyond glycaemic control].

Roca-Rodríguez MM, Muros de Fuentes MT, Piédrola-Maroto G, Quesada-Charneco M, Maraver-Selfa S, Tinahones FJ, Mancha-Doblas I.

Aten Primaria. 2016 Sep 22. pii: S0212-6567(16)30288-8. doi: 10.1016/j.aprim.2016.06.009. [Epub ahead of print] Spanish.

12.

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.

Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, González-Gálvez G, Takami A, Guo H, Niemoeller E, Souhami E, Bergenstal RM; LixiLan-L Trial Investigators..

Diabetes Care. 2016 Nov;39(11):1972-1980.

PMID:
27650977
13.

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.

Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, Cheng X, Zhou T, Niemoeller E, Souhami E, Davies M; LixiLan-O Trial Investigators..

Diabetes Care. 2016 Nov;39(11):2026-2035.

PMID:
27527848
14.

Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.

Forst T.

Expert Opin Pharmacother. 2016 Aug;17(12):1703-8. doi: 10.1080/14656566.2016.1206079.

PMID:
27341040
15.

Postprandial Glucagon Reductions Correlate to Reductions in Postprandial Glucose and Glycated Hemoglobin with Lixisenatide Treatment in Type 2 Diabetes Mellitus: A Post Hoc Analysis.

Ahrén B, Galstyan G, Gautier JF, Giorgino F, Gomez-Peralta F, Krebs M, Nikonova E, Stager W, Vargas-Uricoechea H.

Diabetes Ther. 2016 Sep;7(3):583-90. doi: 10.1007/s13300-016-0179-6.

16.

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

Nauck M, Rizzo M, Johnson A, Bosch-Traberg H, Madsen J, Cariou B.

Diabetes Care. 2016 Sep;39(9):1501-9. doi: 10.2337/dc15-2479.

PMID:
27311491
17.
18.

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.

Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group..

Diabetes Care. 2016 Sep;39(9):1579-86. doi: 10.2337/dc16-0046.

PMID:
27284114
19.

Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials.

Yabe D, Ambos A, Cariou B, Duvnjak L, Evans M, González-Gálvez G, Lin J, Nikonova EV, de Pablos-Velasco P, Yale JF, Ahrén B.

J Diabetes Complications. 2016 Sep-Oct;30(7):1385-92. doi: 10.1016/j.jdiacomp.2016.05.018.

20.

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta-analysis.

Seino H, Onishi Y, Naito Y, Komatsu M.

Diabetol Metab Syndr. 2016 Jun 1;8:36. doi: 10.1186/s13098-016-0151-7.

Items per page

Supplemental Content

Loading ...
Support Center